From the below presentation 60%-65% of the current on-market (auto) treatments will relapse. https://hotcopper.com.au/threads/ann-ceo-presentation-to-the-egm.7602671/
![]()
That's one reason why Michael and Mini were impressed with the ability of iNKT cell secondary remission characteristics (37' 34" in this).
The IMU Azer-Cel acquisition used in conjunction with its onCarlytics platform could be quite successful. An indication of how successful will be the ALA101/onCarlytics in vivo trial results which are pending this quarter.Personally I can't see why IMU would have gone down the Azer-Cel acquisition pathway if they didn't already know that indicative results from the ALA trial were trending positively.
- Forums
- ASX - By Stock
- ALA
- Relapse rate of Auto CD19 CAR T
ALA
arovella therapeutics limited
Add to My Watchlist
1.58%
!
9.4¢

Relapse rate of Auto CD19 CAR T
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
9.4¢ |
Change
-0.002(1.58%) |
Mkt cap ! $112.4M |
Open | High | Low | Value | Volume |
9.5¢ | 9.5¢ | 9.1¢ | $34.16K | 366.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6290 | 9.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.4¢ | 81980 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6290 | 0.093 |
3 | 10877 | 0.092 |
5 | 20543 | 0.091 |
2 | 64822 | 0.090 |
2 | 225000 | 0.089 |
Price($) | Vol. | No. |
---|---|---|
0.094 | 81980 | 1 |
0.095 | 118969 | 3 |
0.096 | 105229 | 2 |
0.097 | 319890 | 2 |
0.098 | 250000 | 1 |
Last trade - 13.50pm 17/09/2025 (20 minute delay) ? |
Featured News
ALA (ASX) Chart |